Denali Therapeutics Inc. $287 Million Initial Public Offering

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the full exercise of the underwriters’ over-allotment option, at $18.00 per share, for total gross proceeds of $287 million.

Denali Therapeutics’ common stock is traded on the NASDAQ Global Select Market under the symbol “DNLI.”

Goldman Sachs & Co. LLC, Morgan Stanley, J.P. Morgan and Evercore ISI acted as underwriters.

Headquartered in South San Francisco, California, Denali Therapeutics is a biopharmaceutical company focused on the discovery and development of therapies for patients with neurodegenerative disease.

The Davis Polk corporate team included partners Alan F. Denenberg (Picture) and Stephen Salmon and associates Connie Y. Lam and Josephine Chen. Counsel David R. Bauer and associates Bonnie Chen provided intellectual property and technology advice. Partner Mario J. Verdolini and associate Catherine L. Chu provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Stephen Salmon – Davis Polk & Wardwell; Connie Lam – Davis Polk & Wardwell; Josephine Chen – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Mario Verdolini – Davis Polk & Wardwell; Catherine Chu – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman, Sachs & Co.; JP Morgan; Morgan Stanley; Evercore Partners;

Print Friendly, PDF & Email

Author: Ambrogio Visconti